```
                    Welcome to DialogClassic Web(tm)
 Dialog level 05.05.00D
Last logoff:  20jul05 09:51:28
Logon file001 21jul05 09:41:56
          *** ANNOUNCEMENT ***
                    ***
--UPDATED: Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                    ***
NEW FILES RELEASED
***Aluminium Industry Abstracts (File 33)
***Ceramic Abstracts/World Ceramic Abstracts (File 335)
***CSA Life Sciences Abstracts (File 24)
***Corrosion Abstracts (File 46)
***Materials Business File (File 269)
***Engineered Materials Abstracts (File 293)
***CSA Aerospace & High Technology Database (File 108)
***CSA Technology Research Database (File 23)
***METADEX(r) (File 32)
***FDAnews (File 182)
***German Patents Fulltext (File 324)
                    ***
RESUMED UPDATING
***Canadian Business and Current Affairs (262)
***CorpTech (559)
                    *** Chemical Structure Searching now available in Prous Science D
of the Future (F453), IMS R&D Focus (F445), Beilstein Facts (F390),
and Derwent Chemistry Resource (F355).
                    ***
     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                    ****
KWIC is set to 50.
HILIGHT set on as ' '
 * * *

File   1:ERIC 1966-2004/Jul 21
       (c) format only 2004 The Dialog Corporation
 *File   1: Updates suspended by ERIC until
Q3, 2005

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?

B 155, 159, 5, 73
       21jul05 09:42:10 User259876 Session D776.1
            $0.80    0.228 DialUnits File1
     $0.80  Estimated cost File1
     $0.05  INTERNET
     $0.85  Estimated cost this search
     $0.85  Estimated total session cost   0.228 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1951-2005/Jul W3
         (c) format only 2005 The Dialog Corp.
  File 159:Cancerlit 1975-2002/Oct
         (c) format only 2002 Dialog Corporation
 *File 159: Cancerlit is no longer updating.
```

```
Please see HELP NEWS159.
  File   5:Biosis Previews(R) 1969-2005/Jul W3
         (c) 2005 BIOSIS
  File  73:EMBASE 1974-2005/Jul 21
         (c) 2005 Elsevier Science B.V.

      Set  Items  Description
      ---  -----  -----------
?

S (MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
          178923  MUCOSAL
          322168  IMMUNITY
         2023142  IMMUNE
           25263  CPG
      S1      69  (MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
?

RD
...examined 50 records  (50)
...completed examining records
      S2      31  RD (unique items)
?

S S2 NOT PY>1998
              31  S2
        10323887  PY>1998
      S3       3  S2 NOT PY>1998
?

T S3/3,K/ALL

  3/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

12599633   PMID: 10189191
 Immunization against hepatitis B virus by mucosal administration of
 antigen-antibody complexes.
  McCluskie M J; Wen Y M; Di Q; Davis H L
  Loeb Health Research Institute, Ottawa, Canada.
  Viral immunology (UNITED STATES) 1998, 11 (4) p245-52, ISSN
0882-8245   Journal Code: 8801552
  Publishing Model Print
  Document type: Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: MEDLINE; Completed

  ... were predominantly of the IgG1 isotype (Th2-like). In contrast,
anti-HBs induced by HBsAg/Ab plus cholera toxin (CT) or
oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs ( CpG
) (1 microg each) were predominantly IgG2a (Th1-like). Results from this
study indicate that HBsAg/Ab complexes can induce strong humoral immune
responses when delivered...


  3/3,K/2     (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.
```

12481550 PMID: 9794366
CpG DNA is a potent enhancer of systemic and mucosal immune **responses against hepatitis B surface antigen with intranasal administration to mice.**
McCluskie M J; Davis H L
Loeb Research Institute, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Canada.
Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Nov 1 1998, 161 (9) p4463-6, ISSN 0022-1767 Journal Code: 2985117R
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

CpG DNA is a potent enhancer of systemic and mucosal immune **responses against hepatitis B surface antigen with intranasal administration to mice.**
...vaccines unless such vaccines are administered with a mucosal adjuvant such as cholera toxin (CT); however, CT is toxic in humans. Synthetic oligodeoxynucleotides containing immunostimulatory **CpG** motifs (**CpG**) are potent adjuvants for the induction of Th1-like systemic immune responses against parenterally delivered proteins. Here, we show in mice that intranasal delivery of hepatitis B surface Ag, which alone has no effect, elicits good immune responses when given with **CpG** oligodeoxynucleotides and/or CT. Overall, **CpG** is superior to CT for the induction of humoral and cell-mediated systemic immunity as well as **mucosal immune** responses (IgA) at local (lung) and distant (feces) sites. Furthermore, **CpG** and CT act synergistically, giving stronger responses than those observed with 10 times more of either adjuvant alone. Ab isotypes were predominantly IgG1 (Th2-like) with CT, mixed IgG1/IgG2a (Th0) with **CpG** , and predominantly IgG2a (Th1-like) with **CpG** and CT together.

3/3,K/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

07454754 EMBASE No: 1998363958
Cutting edge: CpG **DNA is a potent enhancer of systemic and** mucosal immune **responses against hepatitis B surface antigen with intranasal administration to mice**
McCluskie M.J.; Davis H.L.
Dr. H.L. Davis, Loeb Research Institute, 725 Parkdale Avenue, Ottawa, Ont. K1Y 4E9 Canada
AUTHOR EMAIL: hdavis@LRI.ca
Journal of Immunology (J. IMMUNOL.) (United States) 01 NOV 1998, 161/9 (4463-4466)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 32

Cutting edge: CpG **DNA is a potent enhancer of systemic and** mucosal immune **responses against hepatitis B surface antigen with intranasal administration to mice**

Mucosal immunity is difficult to induce with subunit vaccines unless such vaccines are administered with a mucosal adjuvant such as cholera toxin (CT); however, CT is toxic in humans. Synthetic oligodeoxynucleotides containing immunostimulatory **CpG** motifs (**CpG**) are potent adjuvants for

the induction of Th1-like systemic immune responses against parenterally delivered proteins. Here, we show in mice that intranasal delivery of hepatitis B surface Ag, which alone has no effect, elicits good immune responses when given with **CpG** oligodeoxynucleotides and/or CT. Overall, **CpG** is superior to CT for the induction of humoral and cell-mediated systemic immunity as well as **mucosal immune** responses (IgA) at local (lung) and distant (feces) sites. Furthermore, **CpG** and CT act synergistically, giving stronger responses than those observed with 10 times more of either adjuvant alone. Ab isotypes were predominantly IgG1 (Th2-like) with CT, mixed IgG1/IgG2a (Th0) with **CpG** , and predominantly IgG2a (Th1-like) with **CpG** and CT together.
?

```
Set     Items   Description
S1         69   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
S2         31   RD (unique items)
S3          3   S2 NOT PY>1998
?

S (MUCOSAL (W) (IMMUNITY OR IMMUNE)) AND CPG
          178923  MUCOSAL
          322168  IMMUNITY
         2023142  IMMUNE
           10604  MUCOSAL(W)(IMMUNITY OR IMMUNE)
           25263  CPG
      S4     119  (MUCOSAL (W) (IMMUNITY OR IMMUNE)) AND CPG
?

S S4 NOT PY>1998
             119  S4
        10323887  PY>1998
      S5       6  S4 NOT PY>1998
?

RD
...completed examining records
      S6       4  RD (unique items)
?


Set     Items   Description
S1         69   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
S2         31   RD (unique items)
S3          3   S2 NOT PY>1998
S4        119   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) AND CPG
S5          6   S4 NOT PY>1998
S6          4   RD (unique items)
?

S S6 NOT S3
               4  S6
               3  S3
      S7       1  S6 NOT S3
?

T S7/3,K/ALL

  7/3,K/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
```

0011569893 BIOSIS NO.: 199800364140
CpG **DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus**
AUTHOR: Moldoveanu Zina (Reprint); Love-Homan Laurie; Huang Wen Qiang; Krieg Arthur M (Reprint)
AUTHOR ADDRESS: Veterans Adm. Med. Cent., Iowa City, IA 52246, USA**USA
JOURNAL: Vaccine 16 (11-12): p1216-1224 July, 1998 1998
MEDIUM: print
ISSN: 0264-410X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

CpG **DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus**

ABSTRACT: Bacterial DNA causes B cell proliferation, immunoglobulin secretion, and Th1-like cytokine secretion, due to unmethylated **CpG** dinucleotides in particular base contexts (**CpG** motifs), which are far more common in bacterial DNA than in vertebrate DNA. Synthetic oligodeoxynucleotides (ODN) containing **CpG** motifs also trigger immune activation, suggesting possible utility as vaccine enhancers. Mice systemically primed with formalin-inactivated influenza virus mixed with **CpG** ODN, generated virus specific serum antibodies at titres approximately seven times higher than mice immunized without **CpG** ; the titres were further increased following an identical second injection. To determine whether **CpG** could be absorbed through mucosae and enhance vaccination responses, mice were immunized intranasally (IN) with the same preparation of virus with or without **CpG** ODN or Escherichia coli DNA. Following IN immunization, **CpG** ODN or E. coli DNA promoted increased production of influenza-specific antibodies in serum, saliva and the genital tract, compared with the control groups. These studies indicate that stimulatory **CpG** ODN are promising new immune enhancers for vaccination applications.
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: **CpG** DNA...

... **CpG** ODN
MISCELLANEOUS TERMS: **mucosal** **immune** response...
?

```
S (ORAL OR INTRARECTAL OR INTRANASAL) (W) IMMUNIZATION
         1333094  ORAL
            2105  INTRARECTAL
           37411  INTRANASAL
          215001  IMMUNIZATION
      S8    4524  (ORAL OR INTRARECTAL OR INTRANASAL) (W) IMMUNIZATION
?

S S8 (S) ADJUVANT
            4524  S8
          196090  ADJUVANT
      S9     737  S8 (S) ADJUVANT
?

S S9 AND (MUCOASAL (W) (IMMUNITY OR IMMUNE))
             737  S9
               1  MUCOASAL
```

```
          322168  IMMUNITY
         2023142  IMMUNE
               0  MUCOASAL(W)(IMMUNITY OR IMMUNE)
     S10       0  S9 AND (MUCOASAL (W) (IMMUNITY OR IMMUNE))
?


Set     Items   Description
S1         69   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
S2         31   RD (unique items)
S3          3   S2 NOT PY>1998
S4        119   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) AND CPG
S5          6   S4 NOT PY>1998
S6          4   RD (unique items)
S7          1   S6 NOT S3
S8       4524   (ORAL OR INTRARECTAL OR INTRANASAL) (W) IMMUNIZATION
S9        737   S8 (S) ADJUVANT
S10         0   S9 AND (MUCOASAL (W) (IMMUNITY OR IMMUNE))
?

S S9 AND CPG
             737  S9
           25263  CPG
     S11      18  S9 AND CPG
?

S S11 NOT PY>1998
              18  S11
        10323887  PY>1998
     S12       0  S11 NOT PY>1998
?


Set     Items   Description
S1         69   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
S2         31   RD (unique items)
S3          3   S2 NOT PY>1998
S4        119   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) AND CPG
S5          6   S4 NOT PY>1998
S6          4   RD (unique items)
S7          1   S6 NOT S3
S8       4524   (ORAL OR INTRARECTAL OR INTRANASAL) (W) IMMUNIZATION
S9        737   S8 (S) ADJUVANT
S10         0   S9 AND (MUCOASAL (W) (IMMUNITY OR IMMUNE))
S11        18   S9 AND CPG
S12         0   S11 NOT PY>1998
?

RD S11
...completed examining records
     S13       6  RD S11 (unique items)
?

T S13/3,K/ALL

  13/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

18099504   PMID: 15758079
```

Orally administered OVA/ CpG -ODN induces specific mucosal and systemic immune response in young and aged mice.

Alignani Diego; Maletto Belkys; Liscovsky Miriam; Ropolo Andrea; Moron Gabriel; Pistoresi-Palencia Maria C

Departamento de Bioquimica Clinica, CIBICI (CONICET), Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Argentina.

Journal of leukocyte biology (United States) Jun 2005, 77 (6) p898-905, ISSN 0741-5400 Journal Code: 8405628

Publishing Model Print-Electronic

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

Orally administered OVA/ CpG -ODN induces specific mucosal and systemic immune response in young and aged mice.

We have previously demonstrated that subcutaneously administered ovalbumin (OVA) plus synthetic oligodeoxynucleotides containing immunostimulatory **CpG** motifs (**CpG** -ODN) as adjuvant stimulate cellular and humoral immunity and promote T helper cell type 1 differentiation in aged mice. The present study assessed the ability of **CpG** -ODN to induce an OVA-specific immune response after **oral immunization** in young (3-month-old) and aged (18-month-old) BALB/c mice. Oral OVA/ **CpG** -ODN immunization induces a similar OVA-specific T cell-proliferative response (in mucosal and systemic tissues), immunoglobulin G (IgG) in plasma, and IgA in intestinal...

... OVA-specific humoral immune response observed in aged mice was similar to the one observed in young mice, peaking at day 7 after the last **oral immunization** and was present over 40 days after the last **oral immunization** . The pattern of cytokines released in culture supernatants in both groups of mice was similar, with specific interferon-gamma secretion in the absence of interleukin-5 responses. These results provide evidence that orally administered OVA/ **CpG** -ODN induces a young-like, specific, immune response against OVA in aged mice, showing that **CpG** -ODN might be used as a mucosal **adjuvant** during aging.

13/3,K/2 (Item 2 from file: 155)

17746450 PMID: 15734046

Mucosal adjuvants.

Freytag L C; Clements J D

Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA.

Vaccine (Netherlands) Mar 7 2005, 23 (15) p1804-13, ISSN 0264-410X Journal Code: 8406899

Publishing Model Print

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... potential to function as mucosal adjuvants are the ADP-ribosylating enterotoxins (cholera toxin and the heat-labile enterotoxin of Escherichia coli), synthetic oligodeoxynucleotides containing unmethylated **CpG** dinucleotides (**CpG** ODN), and monophosphoryl lipid A (MPL). The mechanism of adjuvanticity of the ADP-ribosylating enterotoxins is the subject of

considerable debate. Our own view is that adjuvanticity is an outcome and not an event. It is likely that these molecules exert their **adjuvant** function by interacting with a variety of cell types, including epithelial cells, dendritic cells, macrophages, and possibly B- and T-lymphocytes. The **adjuvant** activities of **CpG** and MPL are due to several different effects they have on innate and adaptive immune responses and both MPL and **CpG** act through MyD88-dependent and -independent pathways. This presentation will summarize the probable mechanisms of action of these diverse mucosal adjuvants and discuss potential synergy...
Chemical Name: Adjuvants, Immunologic; **CPG** -oligonucleotide; Enterotoxins; Lipid A; Oligodeoxyribonucleotides; monophosphoryl lipid A; Adenosine Diphosphate Ribose

13/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

17455400 PMID: 15603894
Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.
Qu Di; Zheng Bojian; Yao Xin; Guan Yi; Yuan Zheng-Hong; Zhong Nan-Shan; Lu Li-Wei; Xie Jian-Ping; Wen Yu-Mei
Key Laboratory of Medical Molecular Virology/Ministry of Education, Ministry of Public Health, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
Vaccine (Netherlands) Jan 4 2005, 23 (7) p924-31, ISSN 0264-410X Journal Code: 8406899
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... 6) to 10(4.6) times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with **CpG** , or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50...
... immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in **intranasal immunization** with inactivated. SARS-CoV is discussed.

13/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

15460563 PMID: 15331695
Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.
Kang Sang-Moo; Guo Lizheng; Yao Qizhi; Skountzou Ioanna; Compans Richard W
Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, USA.
Journal of virology (United States) Sep 2004, 78 (18) p9624-32, ISSN 0022-538X Journal Code: 0113724
Contract/Grant No.: AI057017-01; AI; NIAID; AI28147; AI; NIAID; AI30042;

AI; NIAID
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... T-lymphocyte activities. The levels of enhancement of immune response by coimmunization with inactivated influenza virus were equivalent to those induced by inclusion of immunostimulatory **CpG** oligodeoxynucleotides (**CpG** DNA). We also observed that SHIV VLPs bind to influenza virus virions, forming mixed aggregates. These results indicate that inactivated influenza virus can play a role as a mucosal **adjuvant** to coadministered antigens.

13/3,K/5 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13621116 PMID: 11207303
Intranasal immunization with CpG **oligodeoxynucleotides as an** adjuvant **dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.**
Gallichan W S; Woolstencroft R N; Guarasci T; McCluskie M J; Davis H L; Rosenthal K L
Centre for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada.
Journal of immunology (Baltimore, Md. - 1950) (United States) Mar 1 2001, 166 (5) p3451-7, ISSN 0022-1767 Journal Code: 2985117R
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Intranasal immunization with CpG **oligodeoxynucleotides as an** adjuvant **dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.**
... HIV, will likely be dependent on the induction of potent long-lasting mucosal immune responses in the genital tract. Recently, synthetic oligodeoxynucleotides (ODN) containing immunostimulatory **CpG** motifs were shown to serve as potent adjuvants for the induction of mucosal immune responses. Here, we show that intranasal immunization with **CpG** ODN, plus recombinant glycoprotein B (rgB) of HSV-1, results in significantly elevated levels of specific anti-gB IgA Abs in vaginal washes that remained ...

...in the genital tract in response to intravaginal (IVAG) HSV-2 challenge. HSV-2-specific CTL were observed at moderate levels in the spleens of **CpG** or non- **CpG** ODN-immunized mice. In contrast, strong CTL responses were observed locally in the genital tissues of both groups following IVAG HSV-2 challenge. Interestingly, mice immunized intranasally with rgB plus **CpG** ODN, but not non- **CpG** ODN, were significantly protected following IVAG HSV-2 challenge. Measurement of virus in protected **CpG** -immunized mice revealed a log lower level of replication within the first few days after infection. In conclusion, these results indicate that intranasal immunization with **CpG** ODN plus protein mediates immunity in the female genital tract capable of protecting against a sexually transmitted pathogen.

Descriptors: *Adjuvants, Immunologic--administration and dosage--AD; * **CpG** Islands--immunology--IM; *Herpes Genitalis--immunology--IM; *Herpes Genitalis--prevention and control--PC; *Herpes Simplex Virus Vaccines --administration and dosage--AD; *Herpesvirus 2, Human--immunology...
Chemical Name: Adjuvants, Immunologic; Antibodies, Viral; **CPG** -oligonucleotide; Herpes Simplex Virus Vaccines; Immunoglobulin A; Immunoglobulin G; Immunoglobulin Isotypes; Oligodeoxyribonucleotides; Recombinant Proteins; Viral Envelope Proteins; glycoprotein B, type 1 herpes simplex virus

13/3,K/6 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12994266 PMID: 10948106
Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants.
Olszewska W; Partidos C D; Steward M W
The Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, United Kingdom.
Infection and immunity (UNITED STATES) Sep 2000, 68 (9) p4923-9, ISSN 0019-9567 Journal Code: 0246127
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... of potent adjuvants for human mucosally delivered vaccines. Novel adjuvant formulations have recently become available, and in the present study two have been used for **intranasal immunization** with a synthetic peptide immunogen (MAP-M2). This peptide represents a multiple antigenic peptide containing multiple copies of a mimotope M2, a peptide mimic of a conformational epitope of the fusion protein of measles virus. MAP-M2 was administered intranasally to experimental animals together with synthetic oligodeoxynucleotides containing unmethylated **CpG** motifs with or without a mutant of wild-type enterotoxin of Escherichia coli (LTR72). The combination of the mutant toxin LTR72 and the **CpG** repeats, codelivered with a peptide immunogen, induced both local and systemic peptide- and pathogen-specific humoral and cellular immune responses comparable to those obtained after **intranasal immunization** with the wild-type toxin LT. In addition, this combination of adjuvants induced a predominantly immunoglobulin G2a antibody response. If both the LTR72 and **CpG** adjuvants are shown to be safe for use in humans, this particular combination would appear to have potential as an **adjuvant** for mucosally delivered vaccines in humans.
?

Set	Items	Description
S1	69	(MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
S2	31	RD (unique items)
S3	3	S2 NOT PY>1998
S4	119	(MUCOSAL (W) (IMMUNITY OR IMMUNE)) AND CPG
S5	6	S4 NOT PY>1998
S6	4	RD (unique items)
S7	1	S6 NOT S3
S8	4524	(ORAL OR INTRARECTAL OR INTRANASAL) (W) IMMUNIZATION
S9	737	S8 (S) ADJUVANT

```
S10          0   S9 AND (MUCOASAL (W) (IMMUNITY OR IMMUNE))
S11         18   S9 AND CPG
S12          0   S11 NOT PY>1998
S13          6   RD S11 (unique items)
?

S S8 AND CPG
            4524  S8
           25263  CPG
     S14      44  S8 AND CPG
?

S S14 NOT PY>1998
              44  S14
        10323887  PY>1998
     S15       0  S14 NOT PY>1998
?


Set     Items   Description
S1         69   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) (S) CPG
S2         31   RD (unique items)
S3          3   S2 NOT PY>1998
S4        119   (MUCOSAL (W) (IMMUNITY OR IMMUNE)) AND CPG
S5          6   S4 NOT PY>1998
S6          4   RD (unique items)
S7          1   S6 NOT S3
S8       4524   (ORAL OR INTRARECTAL OR INTRANASAL) (W) IMMUNIZATION
S9        737   S8 (S) ADJUVANT
S10         0   S9 AND (MUCOASAL (W) (IMMUNITY OR IMMUNE))
S11        18   S9 AND CPG
S12         0   S11 NOT PY>1998
S13         6   RD S11 (unique items)
S14        44   S8 AND CPG
S15         0   S14 NOT PY>1998
?

COST
       21jul05 09:50:19 User259876 Session D776.2
            $4.07    1.198 DialUnits File155
               $1.68  8 Type(s) in Format  3
            $1.68  8 Types
     $5.75  Estimated cost File155
            $0.57    0.182 DialUnits File159
     $0.57  Estimated cost File159
            $7.77    1.317 DialUnits File5
               $0.16  1 Type(s) in Format 95 (KWIC)
            $0.16  1 Types
     $7.93  Estimated cost File5
           $11.87    1.117 DialUnits File73
               $2.94  1 Type(s) in Format  3
            $2.94  1 Types
    $14.81  Estimated cost File73
            OneSearch, 4 files,  3.814 DialUnits FileOS
     $2.40  INTERNET
    $31.46  Estimated cost this search
    $32.31  Estimated total session cost   4.043 DialUnits
?
```

Return to logon page!